{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T01:03:35Z","timestamp":1791594215260,"version":"4.3.4"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,1,21]],"date-time":"2021-01-21T00:00:00Z","timestamp":1611187200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,21]],"date-time":"2021-01-21T00:00:00Z","timestamp":1611187200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100004410","name":"T\u00fcrkiye Bilimsel ve Teknolojik Ara\u015ftirma Kurumu","doi-asserted-by":"publisher","award":["217S847"],"award-info":[{"award-number":["217S847"]}],"id":[{"id":"10.13039\/501100004410","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004410","name":"T\u00fcrkiye Bilimsel ve Teknolojik Ara\u015ftirma Kurumu","doi-asserted-by":"publisher","award":["318S202"],"award-info":[{"award-number":["318S202"]}],"id":[{"id":"10.13039\/501100004410","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01 AI085090"],"award-info":[{"award-number":["R01 AI085090"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Clin Immunol"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1007\/s10875-020-00943-y","type":"journal-article","created":{"date-parts":[[2021,1,21]],"date-time":"2021-01-21T00:03:11Z","timestamp":1611187391000},"page":"769-779","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Stepwise Reversal of Immune Dysregulation Due to STAT1 Gain-of-Function Mutation Following Ruxolitinib Bridge Therapy and Transplantation"],"prefix":"10.1007","volume":"41","author":[{"given":"Basak","family":"Kayaoglu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nurhan","family":"Kasap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naz Surucu","family":"Yilmaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis Marie","family":"Charbonnier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Busranur","family":"Geckin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arzu","family":"Akcay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sevgi Bilgic","family":"Eltan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gulyuz","family":"Ozturk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmet","family":"Ozen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elif","family":"Karakoc-Aydiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talal A.","family":"Chatila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayda","family":"Gursel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4730-9422","authenticated-orcid":false,"given":"Safa","family":"Baris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,21]]},"reference":[{"issue":"1","key":"943_CR1","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1056\/NEJMoa1100102","volume":"365","author":"FL van de Veerdonk","year":"2011","unstructured":"van de Veerdonk FL, Plantinga TS, Hoischen A, Smeekens SP, Joosten LA, Gilissen C, et al. STAT1 mutations in autosomal dominant chronic mucocutaneous candidiasis. N Engl J Med. 2011;365(1):54\u201361.","journal-title":"N Engl J Med"},{"issue":"8","key":"943_CR2","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1084\/jem.20110958","volume":"208","author":"L Liu","year":"2011","unstructured":"Liu L, Okada S, Kong XF, Kreins AY, Cypowyj S, Abhyankar A, et al. Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis. J Exp Med. 2011;208(8):1635\u201348.","journal-title":"J Exp Med"},{"issue":"6","key":"943_CR3","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1007\/s10875-012-9744-6","volume":"32","author":"T Hori","year":"2012","unstructured":"Hori T, Ohnishi H, Teramoto T, Tsubouchi K, Naiki T, Hirose Y, et al. Autosomal-dominant chronic mucocutaneous candidiasis with STAT1-mutation can be complicated with chronic active hepatitis and hypothyroidism. J Clin Immunol. 2012;32(6):1213\u201320.","journal-title":"J Clin Immunol"},{"issue":"5","key":"943_CR4","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/j.jaci.2012.09.011","volume":"130","author":"L Marodi","year":"2012","unstructured":"Marodi L, Cypowyj S, Toth B, Chernyshova L, Puel A, Casanova JL. Molecular mechanisms of mucocutaneous immunity against Candida and Staphylococcus species. J Allergy Clin Immunol. 2012;130(5):1019\u201327.","journal-title":"J Allergy Clin Immunol"},{"key":"943_CR5","doi-asserted-by":"crossref","unstructured":"Kagawa R, Fujiki R, Tsumura M, Sakata S, Nishimura S, Itan Y, et al. Alanine-scanning mutagenesis of human signal transducer and activator of transcription 1 to estimate loss- or gain-of-function variants. J Allergy Clin Immunol. 2016.","DOI":"10.1016\/j.jaci.2016.09.035"},{"issue":"25","key":"943_CR6","doi-asserted-by":"publisher","first-page":"3154","DOI":"10.1182\/blood-2015-11-679902","volume":"127","author":"J Toubiana","year":"2016","unstructured":"Toubiana J, Okada S, Hiller J, Oleastro M, Lagos Gomez M, Aldave Becerra JC, et al. Heterozygous STAT1 gain-of-function mutations underlie an unexpectedly broad clinical phenotype. Blood. 2016;127(25):3154\u201364.","journal-title":"Blood."},{"issue":"5","key":"943_CR7","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1016\/j.jaci.2018.07.020","volume":"142","author":"LR Forbes","year":"2018","unstructured":"Forbes LR, Vogel TP, Cooper MA, Castro-Wagner J, Schussler E, Weinacht KG, et al. Jakinibs for the treatment of immune dysregulation in patients with gain-of-function signal transducer and activator of transcription 1 (STAT1) or STAT3 mutations. J Allergy Clin Immunol. 2018;142(5):1665\u20139.","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"943_CR8","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.jaci.2017.03.049","volume":"141","author":"JW Leiding","year":"2018","unstructured":"Leiding JW, Okada S, Hagin D, Abinun M, Shcherbina A, Balashov DN, et al. Hematopoietic stem cell transplantation in patients with gain-of-function signal transducer and activator of transcription 1 mutations. J Allergy Clin Immunol. 2018;141(2):704\u201317 e5.","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"943_CR9","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.jaci.2014.12.1867","volume":"135","author":"E Higgins","year":"2015","unstructured":"Higgins E, Al Shehri T, McAleer MA, Conlon N, Feighery C, Lilic D, et al. Use of ruxolitinib to successfully treat chronic mucocutaneous candidiasis caused by gain-of-function signal transducer and activator of transcription 1 (STAT1) mutation. J Allergy Clin Immunol. 2015;135(2):551\u20133.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"943_CR10","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.jaci.2018.02.045","volume":"142","author":"K Meesilpavikkai","year":"2018","unstructured":"Meesilpavikkai K, Dik WA, Schrijver B, Nagtzaam NMA, Posthumus-van Sluijs SJ, van Hagen PM, et al. Baricitinib treatment in a patient with a gain-of-function mutation in signal transducer and activator of transcription 1 (STAT1). J Allergy Clin Immunol. 2018;142(1):328\u201330 e2.","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"943_CR11","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1016\/j.jaci.2016.11.022","volume":"139","author":"KG Weinacht","year":"2017","unstructured":"Weinacht KG, Charbonnier LM, Alroqi F, Plant A, Qiao Q, Wu H, et al. Ruxolitinib reverses dysregulated T helper cell responses and controls autoimmunity caused by a novel signal transducer and activator of transcription 1 (STAT1) gain-of-function mutation. J Allergy Clin Immunol. 2017;139(5):1629\u201340 e2.","journal-title":"J Allergy Clin Immunol"},{"issue":"8","key":"943_CR12","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1007\/s10875-019-00687-4","volume":"39","author":"T Al Shehri","year":"2019","unstructured":"Al Shehri T, Gilmour K, Gothe F, Loughlin S, Bibi S, Rowan AD, et al. Novel gain-of-function mutation in Stat1 sumoylation site leads to CMC\/CID phenotype responsive to ruxolitinib. J Clin Immunol. 2019;39(8):776\u201385.","journal-title":"J Clin Immunol"},{"key":"943_CR13","doi-asserted-by":"crossref","unstructured":"Zimmerman O, Rosler B, Zerbe CS, Rosen LB, Hsu AP, Uzel G, et al. Risks of ruxolitinib in STAT1 gain-of-function-associated severe fungal disease. Open Forum Infect Dis. 2017;4(4):ofx202.","DOI":"10.1093\/ofid\/ofx202"},{"issue":"1","key":"943_CR14","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s10875-018-0575-y","volume":"39","author":"A Kiykim","year":"2019","unstructured":"Kiykim A, Charbonnier LM, Akcay A, Karakoc-Aydiner E, Ozen A, Ozturk G, et al. Hematopoietic stem cell transplantation in patients with heterozygous STAT1 gain-of-function mutation. J Clin Immunol. 2019;39(1):37\u201344.","journal-title":"J Clin Immunol"},{"issue":"7","key":"943_CR15","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/s10875-016-0312-3","volume":"36","author":"S Baris","year":"2016","unstructured":"Baris S, Alroqi F, Kiykim A, Karakoc-Aydiner E, Ogulur I, Ozen A, et al. Severe early-onset combined immunodeficiency due to heterozygous gain-of-function mutations in STAT1. J Clin Immunol. 2016;36(7):641\u20138.","journal-title":"J Clin Immunol"},{"issue":"3","key":"943_CR16","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.28071","volume":"67","author":"KM Ramanan","year":"2020","unstructured":"Ramanan KM, Uppuluri R, Ravichandran N, Patel S, Swaminathan VV, Jayakumar I, et al. Successful remission induction in refractory familial hemophagocytic lymphohistiocytosis with ruxolitinib as a bridge to hematopoietic stem cell transplantation. Pediatr Blood Cancer. 2020;67(3):e28071.","journal-title":"Pediatr Blood Cancer"},{"issue":"8","key":"943_CR17","doi-asserted-by":"publisher","first-page":"2790","DOI":"10.1016\/j.jaip.2019.06.011","volume":"7","author":"A Kiykim","year":"2019","unstructured":"Kiykim A, Ogulur I, Dursun E, Charbonnier LM, Nain E, Cekic S, et al. Abatacept as a long-term targeted therapy for LRBA deficiency. J Allergy Clin Immunol Pract. 2019;7(8):2790\u2013800 e15.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"10","key":"943_CR18","doi-asserted-by":"publisher","first-page":"3525","DOI":"10.1016\/j.jaip.2020.07.030","volume":"8","author":"HE Baris","year":"2020","unstructured":"Baris HE, Ogulur I, Akcam B, Kiykim A, Karagoz D, Saraymen B, et al. Diagnostic modalities based on flow cytometry for chronic granulomatous disease: a multicenter study in a well-defined cohort. J Allergy Clin Immunol Pract. 2020;8(10):3525\u201334 e1.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"50","key":"943_CR19","doi-asserted-by":"publisher","first-page":"25222","DOI":"10.1073\/pnas.1908576116","volume":"116","author":"P Mistry","year":"2019","unstructured":"Mistry P, Nakabo S, O\u2019Neil L, Goel RR, Jiang K, Carmona-Rivera C, et al. Transcriptomic, epigenetic, and functional analyses implicate neutrophil diversity in the pathogenesis of systemic lupus erythematosus. Proc Natl Acad Sci U S A. 2019;116(50):25222\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"943_CR20","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1007\/s10875-020-00847-x","volume":"40","author":"S Okada","year":"2020","unstructured":"Okada S, Asano T, Moriya K, Boisson-Dupuis S, Kobayashi M, Casanova JL, et al. Human STAT1 gain-of-function heterozygous mutations: chronic mucocutaneous candidiasis and type I interferonopathy. J Clin Immunol. 2020;40:1065\u201381.","journal-title":"J Clin Immunol"},{"issue":"7","key":"943_CR21","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1093\/cid\/ciw020","volume":"62","author":"R Mossner","year":"2016","unstructured":"Mossner R, Diering N, Bader O, Forkel S, Overbeck T, Gross U, et al. Ruxolitinib induces interleukin 17 and ameliorates chronic mucocutaneous candidiasis caused by STAT1 gain-of-function mutation. Clin Infect Dis. 2016;62(7):951\u20133.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"943_CR22","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s10875-018-0519-6","volume":"38","author":"M Bloomfield","year":"2018","unstructured":"Bloomfield M, Kanderova V, Parackova Z, Vrabcova P, Svaton M, Fronkova E, et al. Utility of ruxolitinib in a child with chronic mucocutaneous candidiasis caused by a novel STAT1 gain-of-function mutation. J Clin Immunol. 2018;38(5):589\u2013601.","journal-title":"J Clin Immunol"},{"issue":"1","key":"943_CR23","doi-asserted-by":"publisher","first-page":"15645","DOI":"10.1038\/s41598-018-34026-1","volume":"8","author":"A Hammitzsch","year":"2018","unstructured":"Hammitzsch A, Chen L, de Wit J, Al-Mossawi MH, Ridley A, Sekine T, et al. Inhibiting ex-vivo Th17 responses in ankylosing spondylitis by targeting Janus kinases. Sci Rep. 2018;8(1):15645.","journal-title":"Sci Rep"},{"issue":"5","key":"943_CR24","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1002\/eji.201847955","volume":"49","author":"E Kaleviste","year":"2019","unstructured":"Kaleviste E, Saare M, Leahy TR, Bondet V, Duffy D, Mogensen TH, et al. Interferon signature in patients with STAT1 gain-of-function mutation is epigenetically determined. Eur J Immunol. 2019;49(5):790\u2013800.","journal-title":"Eur J Immunol"},{"issue":"4","key":"943_CR25","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1007\/s10875-018-0513-z","volume":"38","author":"AE Smyth","year":"2018","unstructured":"Smyth AE, Kaleviste E, Snow A, Kisand K, McMahon CJ, Cant AJ, et al. Aortic calcification in a patient with a gain-of-function STAT1 mutation. J Clin Immunol. 2018;38(4):468\u201370.","journal-title":"J Clin Immunol"},{"issue":"6","key":"943_CR26","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1016\/j.jaci.2017.08.040","volume":"141","author":"A Vargas-Hernandez","year":"2018","unstructured":"Vargas-Hernandez A, Mace EM, Zimmerman O, Zerbe CS, Freeman AF, Rosenzweig S, et al. Ruxolitinib partially reverses functional natural killer cell deficiency in patients with signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations. J Allergy Clin Immunol. 2018;141(6):2142\u201355 e5.","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"943_CR27","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.jaci.2016.10.051","volume":"140","author":"G Tabellini","year":"2017","unstructured":"Tabellini G, Vairo D, Scomodon O, Tamassia N, Ferraro RM, Patrizi O, et al. Impaired natural killer cell functions in patients with signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations. J Allergy Clin Immunol. 2017;140(2):553\u201364 e4.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"943_CR28","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1038\/s41467-018-04013-1","volume":"9","author":"NPD Liau","year":"2018","unstructured":"Liau NPD, Laktyushin A, Lucet IS, Murphy JM, Yao S, Whitlock E, et al. The molecular basis of JAK\/STAT inhibition by SOCS1. Nat Commun. 2018;9(1):1558.","journal-title":"Nat Commun"},{"issue":"6","key":"943_CR29","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1016\/j.jaci.2013.01.004","volume":"131","author":"N Romberg","year":"2013","unstructured":"Romberg N, Morbach H, Lawrence MG, Kim S, Kang I, Holland SM, et al. Gain-of-function STAT1 mutations are associated with PD-L1 overexpression and a defect in B-cell survival. J Allergy Clin Immunol. 2013;131(6):1691\u20133.","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"943_CR30","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1007\/s12185-020-02860-7","volume":"112","author":"K Moriya","year":"2020","unstructured":"Moriya K, Suzuki T, Uchida N, Nakano T, Katayama S, Irie M, et al. Ruxolitinib treatment of a patient with steroid-dependent severe autoimmunity due to STAT1 gain-of-function mutation. Int J Hematol. 2020;112(2):258\u201362.","journal-title":"Int J Hematol"},{"issue":"10","key":"943_CR31","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1002\/pbc.25575","volume":"62","author":"ML Loh","year":"2015","unstructured":"Loh ML, Tasian SK, Rabin KR, Brown P, Magoon D, Reid JM, et al. A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: a Children\u2019s Oncology Group phase 1 consortium study (ADVL1011). Pediatr Blood Cancer. 2015;62(10):1717\u201324.","journal-title":"Pediatr Blood Cancer"}],"container-title":["Journal of Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-020-00943-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10875-020-00943-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-020-00943-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,25]],"date-time":"2021-04-25T02:58:08Z","timestamp":1619319488000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10875-020-00943-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,21]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["943"],"URL":"https:\/\/doi.org\/10.1007\/s10875-020-00943-y","relation":{},"ISSN":["0271-9142","1573-2592"],"issn-type":[{"value":"0271-9142","type":"print"},{"value":"1573-2592","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,21]]},"assertion":[{"value":"29 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by Ethics Committee of Marmara University, School of Medicine. Written informed consents were obtained from the patients and parents.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Informed consent for participation was obtained from all individuals.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Informed publication consent was obtained from all participants.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}]}}